This suggests a continued role for c-IAP2 in tumor therapeutic resistance, and contrasts with our preliminary observations that re-entering cell cycle attenuated sensitivity to Bcl-xL inhibition104. This evidence concerns the gene BCL2L1 and neoplasm.